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European countries (France, Germany, Italy, UK). Additionally
it was tested which inﬂuence a generic product would have on
the relative importance of product attributes. RESULTS: The
conjoint analyses resulted in the fact that there were major dif-
ferences between the relative importance of attributes between
physicians in Europe and the US. In the US efﬁcacy was the most
preferable attribute. Even when a generic drug would enter the
market efﬁcacy would still be the most important attribute—on
a lower level than for the “branded” product market but still the
most important. In Europe the most important attribute was 
the cost. Even when a generic product would enter the market
the costs would be the most important factor. CONCLUSIONS:
The discussions about the increasing health care costs across
Europe could have a major impact on the potential prescribing
behavior of physicians. Even in the breast cancer market which
is highly under public view the pressure on health care budget is
changing the relative importance of products. In the US where
these discussions are not as intensive as in Europe this conclu-
sion cannot be found.
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HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY
PROSTATE CANCER PATIENTS
Wu E1, Mulani P2, Farrell MH1, Sleep D2
1Analysis Group, Inc, Boston, MA, USA, 2Abbott Laboratories, Abbott
Park, IL, USA
OBJECTIVES: To construct and validate a prediction model of
health utility (EQ-5D) for metastatic hormone-refractory prostate
cancer (HRPCA) patients using cancer-speciﬁc health-related
quality of life (HRQL) measures. METHODS: Data were
obtained from a multicenter, multinational observational study
of metastatic HRPCA patients conducted during 2002–2004. In
addition to clinical and resource utilization, health utility (EQ-
5D) and HRQL (Functional Assessment of Cancer Therapy—
Prostate [FACT-P] and European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire [EORTC
QLQ-C30]) data were collected. Predictive validity of ordinary
least square (OLS), Tobit, and median regressions of various
model speciﬁcations were tested using cross-validation samples.
The selected speciﬁcation was then further reﬁned and tested for
alternative model speciﬁcations and restrictions. RESULTS: OLS
regression with both HRQL measures as individual components
and patient demographics was the best performing model. It
explained 58.2% of the observed EQ-5D variation in the valida-
tion sample. A model including only the prostate cancer–speciﬁc
HRQL measure, FACT-P, explained 53.5% of the observed EQ-
5D variation. Both models have good ability to distinguish
patients with high health utility from those with low utility for
cutoff points between the 20th and 80th percentiles of observed
EQ-5D values. CONCLUSIONS: The prediction models devel-
oped have good predictive validity. These algorithms enable
researchers to translate cancer–speciﬁc HRQL measures to health
utility in metastatic HRPCA patients. The ﬁndings will help
perform utility adjustments in cost-utility analyses.
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OBJECTIVES: The purpose of this validation study was to test
the accuracy and acceptability of an Internet-based questionnaire
(Qx) assessing health-related quality of life (HRQoL) among
subjects in CaPSURE, a longitudinal study of health outcomes
among men with prostate cancer. METHODS: Active partici-
pants were sent a ﬂyer with their usual bi-annual Qx offering the
opportunity to test the new Internet version and were paid $25
for their participation. Volunteers were randomized to one of
two Qx administration groups (paper-then-Internet or Internet-
then-paper). The SF-36 and the UCLA Prostate Cancer Index
(PCI) comprised the HRQoL Qx. A 10-item survey designed to
measure patient preference of administration was administered
after completion of both modalities. Descriptive statistics,
Pearson correlation coefﬁcients, and percent agreement were
used to assess comparability between these two methods of
administration. RESULTS: A convenience sample of 245 subjects
volunteered to participate; 209 (85%) completed both paper and
online Qx. Subject median age was 63 years-old (range 46–83).
The majority of respondents were white (97%), college educated
(66%) and had an income of >$75,000/year (46%). With few
exceptions, correlation coefﬁcients for the HRQoL multi-level
items were high (0.66–0.97) and the percent agreement for
yes/no items was also very high (>0.89). Subjects rated both
methods of administration favorably, although the Internet was
rated as somewhat more convenient and faster to complete.
There were no differences between the two versions on respon-
dent ratings for ease of reading, ease of answer completion, con-
fusion or stress. 70% preferred the Internet mode; 21% had no
preference and 9% preferred paper. CONCLUSIONS: Adminis-
tration of the HRQoL Qx, including SF-36 and PCI domains,
demonstrated a high correlation between the Internet and the
paper-and-pencil methods. The Internet was a well-accepted
mode among this select group of older men with prostate cancer.
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OBJECTIVE: Develop/validate a quality of life questionnaire for
capturing the unique spectrum of symptoms and impact on phys-
ical/psychological functioning related to neuroendocrine tumors
and eliciting patients’ own perceptions of their illness, providing
a guide to therapeutic options. METHODS: A total of 103 sub-
jects from a Philadelphia Neuroendocrine Tumor (NET) Con-
ference completed the QOL-NET. Seventy-two subjects were
females (mean age 56.29 + 1.03 years); and 27 were males (mean
age 54.89 + 0.95 years). The population was predominately Cau-
casian (92.2%). On the data, we performed an exploratory
factor analysis using a forced 7-factor varimax rotation. A
descriptive statistical analysis was completed on the total QOL
score and seven factors. Internal consistency was estimated using
Cronbach’s alpha coefﬁcient. Test-retest reliability over a 4–6
week period was assessed by a pairwise t-test on data from a
subset of 20 subjects. RESULTS: All 72 questions loaded into
the 7 domains, which we called: Factor 1 = Depression; Factor
2 = Flushing; Factor 3 = Respiratory; Factor 4 = Gastrointesti-
nal; Factor 5 = Cardiovascular; Factor 6 = Physical Functioning;
Factor 7 = Positive Attitude. Seventy-two items on the forced
seven factor solution accounted for 71.74% of the variance. If
items loaded with a score ≥0.35 on more than one factor, the
highest loading was used. The summary statistics for the Total
QOL and each domain: Total QOL, 76.80 ± 4.80; Factor 1,
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14.96 ± 0.95; Factor 2, 6.10 ± 0.71; Factor 3, 6.24 ± 0.77; Factor
4, 10.58 ± 0.73; Factor 5, 2.61 ± 0.41; Factor 6, 33.96 ± 2.33;
and Factor 7, 2.35 ± 0.30. Physical Functioning proved the
largest and most inﬂuential factor in measuring QOL. Cron-
bach’s alpha was 0.9765, indicating correct allocation of indi-
vidual items to a particular factor. The tool’s robustness was
shown by the test-retest scores, which lacked signiﬁcant differ-
ences between two completions of the questionnaire. CON-
CLUSIONS: QOL-NET should be invaluable for clinical trials.
PCN36
DEVELOPING HEALTH STATE DESCRIPTIONS FOR
METASTATIC COLORECTAL CANCER: QUALITATIVE STUDY
Lloyd A1, van Hanswijck de Jonge P1, Doyle S1,Walker M2,
Cohen C2
1United BioSource Corporation, London, UK; 2Roche Products Ltd,
Welwyn Garden City, Herts, UK
OBJECTIVES: The aim of this study was to develop health state
descriptions for patients with metastatic colorectal cancer
(mCRC)—either stable on treatment, disease progression or
“end of life”. Health states also contrasted intravenous and oral
therapy. These health states can be used subsequently to derive
utility values for use in cost utility analyses. METHODS: An
interview discussion guide was produced based on literature
review and clinical input. This focused on the symptoms of
mCRC, the impact on different areas of functioning (physical,
social, emotional, sexual, and cognitive), and health related
quality of life. Draft health states were developed based on analy-
ses of in-depth exploratory interviews with oncologists (n = 1)
and specialist oncology nurses (n = 3). These health states were
then edited and improved through two further rounds of inter-
views (nurses n = 5; oncologists n = 7; psychometricians n = 2).
The ﬁnal health states were piloted with ﬁve members of the
general public for ease of comprehension and obvious errors of
interpretation. This piloting involved taking the participant
through the full standard gamble interview and then undertak-
ing a full cognitive debrief interview exploring participants’
interpretation of the health states. RESULTS: The analysis of the
literature suggested seven main areas to focus on which included
physical, social, sexual, and cognitive functioning, emotional
wellbeing, side effects and symptoms. The third round of inter-
views with clinical staff indicated that the health states were a
fair reﬂection of the disease. The piloting work also indicated
that members of the general public were able to easily under-
stand the concepts in the health states. No major changes were
required following the pilot work. CONCLUSIONS: Health
states describing the impact of stages of mCRC have been devel-
oped. These health states are designed to be used in societal or
patient based valuation studies. An example ﬁnal health state
will be presented.
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OBJECTIVES: The goal of this study was to estimate an algo-
rithm to convert responses to the Functional Assessment of
Cancer Therapy—General (FACT-G) to current health time
trade-off (TTO) utilities. METHODS: Data for 1433 cancer
patients were randomly separated in to construction and valida-
tion samples. FACT-G questions were selected for inclusion
based upon correlation with ECOG-PS scores and TTO utilities,
and mean scores, and item response theory was used to collapse
response categories. Ordinary least squares regression with the
constant constrained to one was used to estimate the algorithm.
RESULTS: Four FACT-G questions: lack of energy, feel sick, able
to work, and able to enjoy life were selected for the algorithm,
using between two and four response categories each. The algo-
rithm estimated mean utility for the full validation sample within
three points of observed mean utility (0.805 versus 0.832, p <
0.01). Mean utilities are well predicted (difference less than three
percentage points, and not statistically signiﬁcant) for most sub-
groups deﬁned by ECOG-PS and SF-36 physical functioning
scores, and responses to the FACT-G overall quality of life item.
However, the algorithm systematically over-predicted utility for
poor health by each measure. CONCLUSIONS: This algorithm
estimates mean cancer patient preferences for FACT-G based
health states with group level accuracy comparable to other pref-
erence-based measures, and may be applied to both retrospec-
tively and prospectively collected clinical trials data. This
patient-based preference algorithm expands the tools available
for use in cost-utility analyses and treatment comparisons and is
useful in multiple situations, including when the patient is the
primary payer of care, and when understanding how patients
view treatment is desired.
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OBJECTIVES: Propensity score matching fails especially when
there is lack of overlap in the covariate distributions. In this
paper, we analyzed three different methods to adjust propensity
score matching under lack of overlap. METHODS: Most com-
monly used method is to drop all control units with an estimated
propensity score lower than the smallest value, or larger than the
largest value, for the estimated propensity score among the
treated units. The second method is discarding units with covari-
ate values at which the estimated density is below some thresh-
old and newly proposed third method is to estimate average
treatment effect on the optimal subpopulation. RESULTS: The
Market Scan private insurance data base was used in this study
which based upon prostate cancer patients. There was signiﬁ-
cance lack of overlap in data set. Pre-match data set contains
8576 prostate cancer patients and 30,550 control patients. If
one-to-one matching is applied, only 581 patients would match.
Most commonly method described in the methodology section
dropped 1137 patients from control sample. Kernel technique
matched 1250 treatment patients with 2126 control patients. By
using optimal subpopulation, optimal cut-off point is calculated
as 0.02 and it matched 1752 patients from treatment group with
2912 patients in control group. Health care expenditures for
prostate patients using three different methods were signiﬁcantly
different from the ones calculated using one-to-one matching
technique. CONCLUSION: Lack of overlap is the signiﬁcant
drawback of propensity score matching. We can improve
propensity score matching estimands by adjusting overlap dif-
ferences. Optimal subpopulation technique seems better since it
does not rely on arbitrary choices regarding thresholds for dis-
carding observations.
